Hosomi, Koichi
Katayama, Yoichi
Sakoda, Hiroshi
Kikumori, Kunika
Kuroha, Masanori
Ushida, Takahiro
Clinical trials referenced in this document:
Documents that mention this clinical trial
Long-Term Safety and Efficacy of Mirogabalin for Central Neuropathic Pain: A Multinational, Phase 3, 52-Week, Open-Label Study in Asia
https://doi.org/10.1007/s40122-023-00513-1
Usefulness of Mirogabalin in Central Neuropathic Pain After Stroke: Post Hoc Analysis of a Phase 3 Study by Stroke Type and Location
https://doi.org/10.1007/s40122-024-00616-3
Funding for this research was provided by:
Daiichi Sankyo Co., Ltd.
Article History
Received: 19 March 2024
Accepted: 16 May 2024
First Online: 4 July 2024
Declarations
:
: Koichi Hosomi received lecture fees, consulting fees, and contract research funds from Daiichi Sankyo Co., Ltd., lecture fees outside the submitted work from Medtronic Japan Co., Ltd., Boston Scientific Japan K.K., and Nippon Zoki Pharmaceutical Co., Ltd., consulting fees outside the submitted work from Teijin Pharma Ltd., Araya Inc., and the Japanese Society of Psychiatry and Neurology, travel expenses outside the submitted work from Integra Japan Co., Ltd., and grants outside the submitted work from the Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science, and Taiju Life Social Welfare Foundation. Takahiro Ushida received lecture fees and scholarship fees from Daiichi Sankyo Co., Ltd., and lecture fees outside the submitted work from Asahi Kasei Pharma Corp., AbbVie G.K., Viatris Inc., Eisai Co., Ltd., Suzuken Co., Ltd., Shionogi & Co., Ltd., Taisho Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Teijin Pharma Ltd., Nipro Corp., Eli Lilly Japan K.K., Nippon Zoki Pharmaceutical Co., Ltd., Hisamitsu Pharmaceutical Co., Inc., Pfizer Japan Inc., Boston Scientific Japan K.K., Mundipharma K.K., Medical QOL Co., Ltd., Janssen Pharmaceutical K.K., Tsumura & Co., Taisho Toyama Pharmaceutical Co., Ltd., and Mitsubishi Tanabe Pharma Corp. The institution to which Takahiro Ushida is affiliated (Aichi Medical University) received research funding outside the submitted work from Nippon Zoki Pharmaceutical Co., Ltd., Kyoto University, Pascal Universe Co., Ltd., and BonBon Inc., and scholarship fees outside the submitted work from Astellas Pharma Inc., AbbVie G.K., Osuga Clinic, Zenki Clinic, Clinics of Youteikai, Kowa Medical Society, Otsuka Pharmaceutical Co., Ltd., Tsumura & Co., Shionogi & Co., Ltd., Daiichi Sankyo Co., Ltd., Taisho Pharmaceutical Co., Ltd., Taisho Toyama Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Nipro Corp., Eli Lilly Japan K.K., Pfizer Japan Inc., Boston Scientific Japan K.K., and Mochida Pharmaceutical Co., Ltd. Yoichi Katayama has no conflicts of interest to declare. Hiroshi Sakoda, Kunika Kikumori, and Masanori Kuroha are employees of Daiichi Sankyo Co., Ltd., which funded this study.
: The study was conducted in compliance with the ethical principles that have their origins in the Declaration of Helsinki, the International Council for Harmonisation Good Clinical Practice guidelines, and the Japanese Ministry of Health, Labour and Welfare. The study protocol, protocol amendments, informed consent forms, and information sheets were approved by the relevant independent ethics committees or institutional review boards at each study center [], and all patients provided written informed consent prior to participating in the study.